Cargando…

Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177–Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model

Targeted radionuclide therapy (TRT) using probes labeled with Lutetium-177 ((177)Lu) represents a new and growing type of cancer therapy. We studied immunologic changes in response to TRT with (177)Lu labeled anti-human CD20 camelid single domain antibodies (sdAb) in a B16-melanoma model transfected...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ertveldt, Thomas, De Beck, Lien, De Ridder, Kirsten, Locy, Hanne, de Mey, Wout, Goyvaerts, Cleo, Lecocq, Quentin, Ceuppens, Hannelore, De Vlaeminck, Yannick, Awad, Robin Maximilian, Keyaerts, Marleen, Devoogdt, Nick, D'Huyvetter, Matthias, Breckpot, Karine, Krasniqi, Ahmet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Small Molecule Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377759/ https://www.ncbi.nlm.nih.gov/pubmed/35499391 http://dx.doi.org/10.1158/1535-7163.MCT-21-0791

Ejemplares similares

Theranostics in immuno-oncology using nanobody derivatives
por: Lecocq, Quentin, et al.
Publicado: (2019)

Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade
por: Lecocq, Quentin, et al.
Publicado: (2021)

The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy
por: Puttemans, Janik, et al.
Publicado: (2022)

Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade
por: Awad, Robin Maximilian, et al.
Publicado: (2021)

In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4(+) T cells
por: Awad, Robin Maximilian, et al.
Publicado: (2023)

TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy
por: De Ridder, Kirsten, et al.
Publicado: (2022)

Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use
por: Lecocq, Quentin, et al.
Publicado: (2019)

Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer
por: Lecocq, Q., et al.
Publicado: (2021)

Targeted Radionuclide Therapy with A (177)Lu-labeled Anti-HER2 Nanobody
por: D'Huyvetter, Matthias, et al.
Publicado: (2014)

Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases
por: Puttemans, Janik, et al.
Publicado: (2019)

Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT
por: Zeven, Katty, et al.
Publicado: (2023)

Preclinical Targeted α- and β(−)-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies
por: Puttemans, Janik, et al.
Publicado: (2020)

CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma
por: De Veirman, Kim, et al.
Publicado: (2021)

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
por: Ruigrok, Eline A. M., et al.
Publicado: (2020)

Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
por: D’Huyvetter, Matthias, et al.
Publicado: (2014)

Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle
por: Dekempeneer, Yana, et al.
Publicado: (2016)

The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm
por: Lecocq, Quentin, et al.
Publicado: (2020)

Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8(+) T cell and iNKT cell activating mRNA vaccine
por: Ertveldt, Thomas, et al.
Publicado: (2023)

Cancer-Associated Myeloid Regulatory Cells
por: De Vlaeminck, Yannick, et al.
Publicado: (2016)

Preclinical Evaluation of (225)Ac-Labeled Single-Domain Antibody for the Treatment of HER2(pos) Cancer
por: Rodak, Magdalena, et al.
Publicado: (2022)

Software-assisted dosimetry in peptide receptor radionuclide therapy with (177)Lutetium-DOTATATE for various imaging scenarios
por: Kupitz, Dennis, et al.
Publicado: (2017)

Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
por: Awad, Robin Maximilian, et al.
Publicado: (2018)

Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)
por: Hosono, Makoto, et al.
Publicado: (2018)

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
por: Broos, Katrijn, et al.
Publicado: (2018)

Challenges and future options for the production of lutetium-177
por: Vogel, W. V., et al.
Publicado: (2021)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy
por: Funeh, Cyprine Neba, et al.
Publicado: (2023)

Critical Appraisal of Radionuclide Calibrators and Gamma Cameras Prior to Lutetium-177 Internal Dosimetry at Two South African Hospitals
por: Van Wyk, Bronwin P., et al.
Publicado: (2022)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
por: Gadot, Moran, et al.
Publicado: (2020)

Inter-comparison of quantitative imaging of lutetium-177 ((177)Lu) in European hospitals
por: Wevrett, Jill, et al.
Publicado: (2018)

Results and adverse events of personalized peptide receptor radionuclide therapy with (90)Yttrium and (177)Lutetium in 1048 patients with neuroendocrine neoplasms
por: Baum, Richard P., et al.
Publicado: (2018)

Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
por: Emmett, Louise, et al.
Publicado: (2017)

A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy
por: Yang, Tianhong, et al.
Publicado: (2023)

(177)Lutetium SPECT/CT: Evaluation of collimator, photopeak and scatter correction
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend
por: Locy, Hanne, et al.
Publicado: (2018)

Lutetium-177-PSMA-617: A Vision of the Future
por: Chandran, Elias, et al.
Publicado: (2022)

Lutetium Lu 177 Vipivotide Tetraxetan: First Approval
por: Keam, Susan J.
Publicado: (2022)

Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals
por: Ladrière, Typhanie, et al.
Publicado: (2023)

An mRNA mix redirects dendritic cells towards an antiviral program, inducing anticancer cytotoxic stem cell and central memory CD8(+) T cells
por: de Mey, Wout, et al.
Publicado: (2023)

In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_prp8aoe1jjtk2o5h5641oppnom